Physician profile
Mark E Posnick
NPI 1194218834
$3,644.67
in general payments reported to CMS, 2019-2025
15 companies · $779 in 2025
The $779 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $15.64 · 2021: $557 · 2022: $1,128 · 2023: $442 · 2024: $433 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,652.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $696.61 | 2021-2025 | |
| Abbvie INC. | $596.59 | 2021-2024 | |
| Ucb, INC. | $456.28 | 2022-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $352.12 | 2021-2025 | |
| Galderma Laboratories, L.P. | $256.73 | 2024-2025 | Nemluvio |
| Incyte Corporation | $210.83 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $183.15 | 2022-2025 | |
| Lilly USA, LLC | $175.78 | 2021-2024 | Olumiant |
| Sanofi-Aventis U.S. LLC | $168.58 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $133.54 | 2022 | |
| Amgen INC. | $114.22 | 2022 | |
| Pfizer INC. | $92.64 | 2019 | |
| Janssen Scientific Affairs, LLC | $71.12 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.34 | 2019-2020 | |
| Glaxosmithkline, LLC. | $15.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Posnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.